Bottom line
XLV vs FTXH: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and FTXH (First Trust Nasdaq Pharmaceuticals ETF) share a meaningful slice of their top holdings — about 50% by weight.
XLV is cheaper at 0.08% vs 0.6% — a difference of $52 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +6.5% for FTXH.
Updated Nov 19, 2026
XLV vs FTXH side by side
| XLV | FTXH | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | SPDR (State Street) | First Trust |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 0.6% |
| Annual cost per $10k | $8 | $60 |
| 10-yr cost on $10k (prospectus) | $103 | — |
| Max front load | None | None |
| 12b-1 fee | 0.02% | 0% |
| 1-yr return | +14.5% | +24.0% |
| 5-yr return (annualized) | +8.1% | +6.5% |
| 10-yr return (annualized) | +9.8% | — |
| Best quarter | +14.5% | +18.3% |
| Worst quarter | −12.7% | −17.4% |
| Net assets (fund) | $40.6B | $36.2M |
| Number of holdings | 65 | 51 |
| Portfolio turnover | 2% | 35% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XLV | FTXH | Difference |
|---|---|---|---|
| 2025 | +14.5% | +24.0% | −9.5% |
| 2024 | +2.5% | +3.0% | −0.5% |
| 2023 | +2.0% | −1.4% | +3.4% |
| 2022 | −2.1% | +2.5% | −4.6% |
| 2021 | +25.9% | +6.1% | +19.8% |
| 2020 | +13.3% | +10.9% | +2.4% |
| 2019 | +20.7% | +22.4% | −1.7% |
| 2018 | +6.3% | −8.4% | +14.6% |
| 2017 | +21.7% | +18.8% | +2.9% |
Source: Fund prospectus bar charts
Holdings overlap
11 of XLV's top 25 holdings also appear in FTXH's top 25.
| Holding | XLV | FTXH |
|---|---|---|
| Eli Lilly & Co | 16.51% | 7.77% |
| Johnson & Johnson | 10.64% | 6.96% |
| AbbVie Inc | 7.74% | 7.39% |
| Merck & Co Inc | 5.52% | 7.07% |
| Amgen Inc | 3.40% | 3.18% |
| Gilead Sciences Inc | 2.73% | 2.89% |
| Pfizer Inc | 2.39% | 2.97% |
| Vertex Pharmaceuticals Inc | 2.19% | 3.41% |
| Bristol-Myers Squibb Co | 2.05% | 6.29% |
| Regeneron Pharmaceuticals Inc | 1.08% | 2.72% |
| Cardinal Health Inc | 0.97% | 3.53% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
FTXH top 10
- Eli Lilly & Company — 7.77%
- Abbvie Inc — 7.39%
- Merck & Company Inc — 7.07%
- Johnson & Johnson — 6.96%
- Bristol-myers Squibb Company — 6.29%
- Biogen Inc — 3.84%
- Viatris Inc — 3.62%
- Cardinal Health Inc — 3.53%
- Vertex Pharmaceuticals Inc — 3.41%
- Amgen Inc — 3.18%
FAQ
What is the difference between XLV and FTXH?
Which is cheaper, XLV or FTXH?
Should I own both XLV and FTXH?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.